Oregon, Illinois Medicaid Programs Place Tight Restrictions On Gilead $1,000-Per-Pill Hepatitis C Drug Sovaldi
An Oregon Medicaid committee is expected Thursday to significantly scale back access to an effective—but expensive—new drug used to treat hepatitis C, the second state to retrict access to the drug in two days.
The maker of a hepatitis C drug that costs about $1,000 per pill on Wednesday delivered a quarterly earnings report that shattered expectations, showing the company tripled its profit which is now in the billions.
Doctors are calling a newly-approved drug a “ revolution” in treating the most common blood-borne infection in the United States. But patient advocates warn how those who need it may not be able to afford it; and noisy protests from Paris to San Francisco are trying to drive the displeasure over the price into the open.
Gilead Sciences said Monday that the Food and Drug Administration rejected two marketing applications for HIV treatments, citing quality control problems at the Foster Citry company’s manufacturing facilities.
The first drug shown to prevent HIV infection won the endorsement of a panel of federal advisers Thursday, clearing the way for a landmark approval in the 30-year fight against the virus that causes AIDS.
The UC-based California HIV/AIDS Research Program (CHRP) has awarded grants totaling $11.8 million to see if a current HIV drug can be used to prevent the onset of the virus.
California’s treasurer on Friday became the second state official to ask leading makers of AIDS medications to extend lower prices and rebates for drugs to help the state’s budget crisis.
California’s State Controller has asked that pharmacuetical companies lower the price of AIDS medications.
A promising drug shown to decrease the likelihood of transmitting HIV should only be prescribed to men at high risk who are closely monitored by a doctor, federal health officials said Friday.